glucose, (beta-d)-isomer has been researched along with Colitis-Associated Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, YE; Guan, T; Hou, S; Liang, J; Liu, Y; Lu, Y; Shen, Q; Xu, S; Zhu, S | 1 |
| Duan, YQ; Li, Z; Luo, YP; Ma, XM; Si, XL; Song, BN; Wang, Y; Yang, QX; Zhang, Y; Zhang, YY | 1 |
2 other study(ies) available for glucose, (beta-d)-isomer and Colitis-Associated Cancer
| Article | Year |
|---|---|
Asperuloside inhibited epithelial-mesenchymal transition in colitis associated cancer via activation of vitamin D receptor.
Topics: Animals; Colitis-Associated Neoplasms; Cyclopentane Monoterpenes; Epithelial-Mesenchymal Transition; Glucosides; Lipopolysaccharides; Mice; NF-kappa B; Pyrans; Receptors, Calcitriol; RNA, Messenger; Transforming Growth Factor beta1 | 2022 |
Potential Chemoprevention of Paeoniflorin in Colitis-Associated Colorectal Cancer by Network Pharmacology, Molecular Docking, and In Vivo Experiment.
Topics: Animals; Cell Transformation, Neoplastic; Chemoprevention; Colitis-Associated Neoplasms; Colorectal Neoplasms; Disease Models, Animal; Glucosides; Interleukin-6; Mice; Molecular Docking Simulation; Monoterpenes; Network Pharmacology; STAT3 Transcription Factor | 2022 |